Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Monday, November 8, 2010

Telbivudine Prevents HBV Perinatal Transmission

Limited use of telbivudine in highly viremic pregnant women can reduce perinatal hepatitis B virus (HBV) transmission to infants, according to the results of a study presented here at AASLD 2010.

Previous studies have shown that lamivudine used in the third trimester of pregnancy can significantly reduce HBV transmission. However, the incidence of teratogenicity with telbivudine in animals has restricted its use in pregnant women.

Read More.....

No comments:

Post a Comment